Tesla's problems, Eli Lilly's weight loss pill, and egg prices surge: Business news roundup
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
Eli Lilly and Company (LLY): Jim Cramer Says ‘Don’t Sell’ – A Visionary Stock to Hold!
We recently published a list of Jim Cramer Commented On These 6 Stocks Recently. In this article, we are going to take a look ...
Eli Lilly and Company (LLY): Among The Stocks With At Least $10 Million In Insider Sales Recently
We recently compiled a list of the 10 Stocks With At Least $10 Million In Insider Sales Recently. In this article, we are ...
GE Aerospace to invest nearly $1B in US manufacturing
GE Aerospace is the latest company to announce an investment in the U.S. economy under the Trump administration. GE said the ...
Independent Journal Review10d
Business Giants, Foreign Countries Have Already Committed To Pouring Over $1 Trillion Into US Since Trump’s Return
A bevy of major corporations and foreign countries have pledged to pour billions into the U.S. since President Donald Trump ...
The Financial Express13d
Pfizer may soon move its overseas manufacturing to United States to counter potential tariff hit
Pfizer CEO Albert Bourla on Monday said that the company might move overseas manufacturing to its existing plants in the ...
Eli Lilly: A Safe Harbor Amid Market Volatility
Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...
Citi sees positive read-through to Lilly shares on FDA GLP-1 statement
Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...
Eli Lilly snaps six days of losses
Eli Lilly (LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...
FDA voices ‘concerns’ with unapproved GLP-1 drugs used for weight loss
FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...